drugset / Press release
The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
2019-02-06 · Trio Medicines Ltd. · original triomedicines.com ↗
The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Kidd M, Siddique Z, Drozdov I, Gustafsson B, Camp R, Black JW, Boyce M, Modlin I. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL-cell hyperplasia and gastric carcinoid tumor development. Regul Pept 2010; 162: 52–60.
The release as fetched from its publisher. triomedicines.com ↗